Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantationMélanie Roland, Jean‐Michel Halimi, Hubert Nivet et al.|Transplant International|2008Cited by 63
Autosomal dominant polycystic kidney disease: risk factor for nonmelanoma skin cancer following kidney transplantationAnne Bretagnol, Matthias Büchler, Jean‐Michel Halimi et al.|Transplant International|2010Cited by 26
Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus?Jean‐Michel Halimi, Bruno Giraudeau, Bénédicte Sautenet et al.|Fundamental and Clinical Pharmacology|2011Cited by 14
Doubling of Serum Creatinine in Clinical Trials, Cost-Effectiveness Studies, and Individual Patients: Adequate Use in Renal TransplantationPhilippe Gatault, Jean‐Michel Halimi, Hubert Nivet et al.|Transplantation|2011Cited by 5